Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 9/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21072961 | 0.84 | RORC (0.50) | PKMRORC | |
| SCHEMBL21073502 | 0.84 | RORC (0.51) | RORC | |
| SCHEMBL21072988 | 0.83 | RORC (0.52) | PKMRORC | |
| SCHEMBL21073503 | 0.83 | PKM (0.62) | PKMRORC | |
| SCHEMBL21072889 | 0.83 | MAPT (0.63) | MEN1KMT2ARORC | |
| SCHEMBL21787473 | 0.82 | RORC (0.42) | RORC | |
| SCHEMBL21073134 | 0.81 | RORC (0.52) | RORC | |
| SCHEMBL21072887 | 0.81 | RORC (0.51) | RORC | |
| SCHEMBL21073154 | 0.80 | RORC (0.51) | PKMRORC | |
| SCHEMBL21073158 | 0.78 | RORC (0.63) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161837-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210161837-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-03 | — | — | US | disclosed |
| US-20190192454-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190192454-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192454-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | RORA, RORB, RORC | PKM 3347/4885LMNA 3433/4885MEN1 2278/4885 |
| US-20210161837-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | RORA, RORB, RORC | PKM 3347/4885LMNA 3433/4885MEN1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.